Genetic Aberrations in Oral Dysplasia Point to Cancer Progression

Published Online: Tuesday, September 18, 2012
Follow Pharmacy_Times:

Chromosomal changes at the allele level were recently found to influence the progression of oral dysplasia into malignant lesions, according to a new prospective study of 296 patients with mild or moderate keratotic abnormalities.

To fully understand how oral precancers can become cancerous, scientists in this study used their prior research, which showed that loss of heterozygosity (LOH) on the short arms of chromosomes 3 and 9 was associated with oral cancer development. LOH occurs when a somatic cell heterozygous for a deleterious mutant allele and a normal allele goes through a deletion or other mutational event on the normal copy, rendering the gene inactive. This gene inactivation could stop the production of tumor suppressor genes.

Investigators grouped the patients into low-, intermediate-, and high-risk groups based on the chromosomal location of the LOH. Five-year progression rates were found to be 3.1% for the low-risk group, 16.3% for the intermediate-risk group, and 63.1% for the high-risk group. This means that 2 of 3 high-risk cases are progressing, according to the study authors.



Related Articles
Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.
Priced at approximately $178,000 for 2 courses of treatment, Blincyto will be one of the most expensive cancer medications on the market.
The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.
Merck’s anti–PD-1 therapy Keytruda has demonstrated an overall response rate of 18.5% among patients with PD-L1 positive, advanced triple-negative breast cancer, one of the most aggressive forms of breast cancer.
Latest Issues
$auto_registration$